New Delhi: Piramal Healthcare today said it has completed the first phase of clinical trials of a new oral drug for treating cancer and will move to the next stage of development.The company said it has established safety, apart from determining maximum tolerated dosages in humans for its new molecule code named P1446A-05 in multi-centric Phase-I trials conducted in India and Canada."We are extremely pleased with the results of the P1446A -05 and are committed to moving the molecule further in clinical development for the treatment of cancer," Piramal Healthcare Director Swati Piramal said in a statement.The data of the Phase-I trials will be presented at the annual meeting of American Society for Clinical Oncology to be held in Chicago from June 1-5 this year, the company said.The results of trials conducted in India and Canada, each investigating two different dosing schedules, will be reported in the meeting, it added."The completion of these two phase I studies readies P1446A-05...To enter into a broader context of clinical development across a spectrum of malignant diseases. It offers continuous exposure to the targets and has a profile that can be integrated with other therapies," Piramal Healthcare Executive Vice-President Clinical Research Alan Hatfield said.Phase I clinical trials are conducted on a limited small number of human beings to establish safety, efficacy and check side effects on new drug molecules.
Narendra Modi sent emissaries to me: Geelani
Modi to file nomination from Varanasi on April 24 : Amit Shah
Now a book from RAW, more damage awaits UPA
Vote for Supriya Sule or lose water supply, threatens Ajit Pawar